Science Explorer Back to mapMap
Discussion
Institution · Cardiovascular Center Bethanien

Most cited papers from Cardiovascular Center Bethanien

Cardiovascular Center Bethanien

What are the most cited papers from Cardiovascular Center Bethanien?

The most cited paper from Cardiovascular Center Bethanien is "Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer" (Gϋnter von Minckwitz et al., 2018), with 2,689 citations. Next come "Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer" (1,744) and "Breast cancer" (1,696).

Showing 50 of 59 papers. Every paper with more than 148 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer Gϋnter von Minckwitz et al. · New England Journal of Medicine Open access 5 Dec 2018 2,689
2 Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer Andrew N.J. Tutt et al. · New England Journal of Medicine Open access 3 Jun 2021 1,744
3 Breast cancer Sibylle Loibl, Philip M. Poortmans, Monica Morrow et al. · The Lancet 2 Apr 2021 1,696
4 Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial Gϋnter von Minckwitz et al. · The Lancet Oncology 30 Apr 2014 1,048
5 Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Sibylle Loibl et al. · Annals of Oncology Open access 13 Dec 2023 991
6 Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial Sibylle Loibl, Joyce O’Shaughnessy, Michael Untch et al. · The Lancet Oncology 28 Feb 2018 781
7 Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer Nicholas C. Turner et al. · New England Journal of Medicine Open access 31 May 2023 780
8 Coronary Risk Stratification, Discrimination, and Reclassification Improvement Based on Quantification of Subclinical Coronary Atherosclerosis Raimund Erbel, Stefan Möhlenkamp, Susanne Moebus et al. · Journal of the American College of Cardiology Open access Oct 2010 772
9 A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study S. Loibl et al. · Annals of Oncology Open access 7 May 2019 714
10 Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry Lucas V.A. Boersma, Lucas V.A. Boersma, Boris Schmidt et al. · European Heart Journal Open access 27 Jan 2016 526
11 Global experience in cervical carotid artery stent placement Michael Henry Wholey et al. · Catheterization and Cardiovascular Interventions Open access Jun 2000 508
12 Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study Emmanuel Ekanem et al. · Nature Medicine Open access139 authors Jul 2024 484
13 Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Charles E. Geyer et al. · Annals of Oncology Open access609 authors 10 Oct 2022 477
14 Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial Michael Untch, Sibylle Loibl, Joachim Bischoff et al. · The Lancet Oncology 16 Jan 2012 459
15 Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial Lucas V.A. Boersma, Hueseyin Ince, Stephan Kische et al. · Heart Rhythm Open access Jun 2017 439
16 One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry Miriam Puls, Edith Lubos, Peter Boekstegers et al. · European Heart Journal Open access 27 Nov 2015 436
17 Percutaneous Left Atrial Appendage Transcatheter Occlusion to Prevent Stroke in High-Risk Patients With Atrial Fibrillation Horst Sievert, Michael D. Lesh, Thomas Trepels et al. · Circulation Open access 23 Apr 2002 436
18 Thoracic Endovascular Aortic Repair (TEVAR) for the treatment of aortic diseases: a position statement from the European Association for Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Martin Grabenwöger, Fernándo Alfonso, Jean E. Bachet et al. · European Heart Journal Open access 4 May 2012 412
19 Risk of stroke after transcatheter aortic valve implantation (TAVI): a meta-analysis of 10,037 published patients Holger Eggebrecht, Axel Schmermund, Thomas Voigtländer et al. · EuroIntervention Review May 2012 408
20 Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial Dhanunjaya Lakkireddy, David Thaler, Christopher R. Ellis et al. · Circulation Open access 30 Aug 2021 407
21 International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants Robert C. Gosselin, Dorothy M. Adcock, Shannon M. Bates et al. · Thrombosis and Haemostasis Open access 12 Feb 2018 392
22 Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One-Year Outcomes From the MANIFEST-PF Registry Mohit K. Turagam et al. · Circulation Open access 18 May 2023 378
23 Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial Karl-Heinz Kuck, Alexander Fürnkranz, K. R. Julian Chun et al. · European Heart Journal Open access 5 Jul 2016 354
24 Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial Sibylle Loibl et al. · Journal of Clinical Oncology Apr 2021 332
25 Bioresorbable Coronary Scaffold Thrombosis Serban Puricel, Florim Cuculi, Melissa Weissner et al. · Journal of the American College of Cardiology Open access 22 Feb 2016 316
26 EUropean real-world outcomes with Pulsed field ablatiOn in patients with symptomatic atRIAl fibrillation: lessons from the multi-centre EU-PORIA registry Boris Schmidt, Stefano Bordignon, Kars G.E.J. Neven et al. · EP Europace Open access 28 Jun 2023 308
27 Myocardial Late Gadolinium Enhancement: Prevalence, Pattern, and Prognostic Relevance in Marathon Runners Frank Breuckmann, Stefan Möhlenkamp, Kai Naßenstein et al. · Radiology 31 Mar 2009 292
28 Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology Lucas V.A. Boersma et al. · Circulation Arrhythmia and Electrophysiology Open access Apr 2019 288
29 Procedural results and acute complications in stenting native and recurrent coarctation of the aorta in patients over 4 years of age: A multi‐institutional study Thomas J. Forbes et al. · Catheterization and Cardiovascular Interventions 13 Jul 2007 255
30 Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial Carsten Denkert, Sibylle Loibl, Berit Maria Müller et al. · Annals of Oncology Open access 23 Aug 2013 249
31 Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023 Giuseppe Curigliano et al. · Annals of Oncology Open access 6 Sep 2023 242
32 Systemic therapy in metastatic renal cell carcinoma Jens Bedke, Thomas Christoph Gauler, Viktor Grünwald et al. · World Journal of Urology Open access 9 Jun 2016 233
33 Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial Charles E. Geyer et al. · Annals of Oncology Open access 30 Jan 2022 227
34 Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial Arlene Chan et al. · Clinical Breast Cancer Open access 5 Oct 2020 221
35 Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial Nadia Harbeck et al. · Nature Medicine Open access 13 Sep 2024 216
36 Value of Progression of Coronary Artery Calcification for Risk Prediction of Coronary and Cardiovascular Events Nils Lehmann et al. · Circulation Open access 15 Nov 2017 216
37 Advances in the treatment of advanced oestrogen-receptor-positive breast cancer Nicholas C. Turner, Patrick Neven, Sibylle Loibl et al. · The Lancet 6 Dec 2016 211
38 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants Jonathan Douxfils, Dorothy M. Adcock, Shannon M. Bates et al. · Thrombosis and Haemostasis Open access 19 Mar 2021 209
39 Reduction in radiation exposure in cardiovascular computed tomography imaging: results from the PROspective multicenter registry on radiaTion dose Estimates of cardiac CT angIOgraphy iN daily practice in 2017 (PROTECTION VI) Thomas J. Stocker et al. · European Heart Journal Open access143 authors 22 Aug 2018 205
40 Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer Barbara Ingold Heppner et al. · Clinical Cancer Research 17 May 2016 204
41 Transcatheter closure of patent foramen ovale in patients with cerebral ischemia MARTIN U. BRAUN, Dieter Faßbender, Steffen P. Schoen et al. · Journal of the American College of Cardiology Open access Jun 2002 202
42 Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer Hope S. Rugo, Fabrice André, Toshinari Yamashita et al. · Annals of Oncology Open access 13 May 2020 196
43 A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study Holger Reinecke, Christiane M. Engelbertz, Rupert Martin Bauersachs et al. · Circulation Open access 6 Nov 2022 188
44 Repeat Ablation for Atrial Fibrillation Recurrence Post Cryoballoon or Radiofrequency Ablation in the FIRE AND ICE Trial Karl-Heinz Kuck et al. · Circulation Arrhythmia and Electrophysiology Open access 22 May 2019 185
45 High dose and long-term statin therapy accelerate coronary artery calcification Michael Y. Henein, Gabriel Granåsen, Urban Wiklund et al. · International Journal of Cardiology 24 Feb 2015 185
46 Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer Gϋnter von Minckwitz et al. · Clinical Cancer Research Open access 29 Jun 2013 176
47 Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves Sabine Bleiziffer et al. · European Heart Journal Open access 22 Jun 2020 173
48 Left atrial appendage occlusion with the Amplatzer™ Amulet™ device: full results of the prospective global observational study David Hildick‐Smith, Ulf Landmesser, A. John Camm et al. · European Heart Journal Open access 26 Feb 2020 172
49 Intermediate follow‐up following intravascular stenting for treatment of coarctation of the aorta Thomas J. Forbes et al. · Catheterization and Cardiovascular Interventions Open access 25 Sep 2007 172
50 Quantification of Coronary Atherosclerosis and Inflammation to Predict Coronary Events and All-Cause Mortality Stefan Möhlenkamp, Nils Lehmann, Susanne Moebus et al. · Journal of the American College of Cardiology Open access Mar 2011 171

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.